TORM plc vs Zimmer Biomet Holdings Inc — how do they compare? TORM plc trades at $28.84 (market cap $2.93B), while Zimmer Biomet Holdings Inc trades at $96.76 (market cap $18.55B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 6.3× TORM plc's market cap, and TORM plc pays the higher dividend (9.77%). Which is the better fit depends on your goals.
| TRMD | ZBH | |
|---|---|---|
Market Cap | $2.93B | $18.55B |
Sector | Technology | Health |
52-Week High | $34.87 | $107.71 |
52-Week Low | $18.77 | $79.58 |
Enterprise Value | $3.82B | $25.61B |
Dividend Yield | 9.77% | 0.99% |
Signals from Pluang's Aura AI — not financial advice
TRMD trades at $28.84, down 1.2% with a bearish technical signal despite strong fundamentals. The company reported robust 2025 results with $1.34B revenue, $285.3M net income, and a 24.41% net margin. Recent earnings show mixed performance with Q2 2026 expectations at $3.41 EPS. Analyst consensus remains unanimously bullish with 3 buy ratings. Technical indicators show oversold conditions with RSI at 24.63, while support levels cluster around $28.
The stock presents a value opportunity with attractive valuation multiples (P/E 8.4, EV/EBITDA 5.95) and strong profitability metrics (ROE 15.62%). Near-term catalysts include Q2 2026 earnings and the $0.70 dividend payment in June. Key risks include earnings volatility, tanker market cyclicality, and negative cash flow trends. Institutional ownership stability and positive analyst coverage support the bullish case despite technical weakness.
ZBH trades at $96.04, down 1.78% today, with a bullish technical signal from moving averages and a consensus analyst price target of $103.56. Recent Q2 2026 earnings beat expectations with EPS of $2.07 versus $2.01 expected, and the company raised its 2026 outlook. Revenue growth remains steady, with 2025 revenue at $8.23 billion and a net income margin of 8.56%.
The outlook is positive given earnings momentum and raised guidance, but risks include competitive pressures and debt levels, with the debt-to-asset ratio rising to 32.57% in 2025. Analyst sentiment is mixed with 40% buy ratings, offering a potential 7.8% upside to the consensus target, though investors should monitor margin trends and debt management.
Trailing returns across standard periods
TORM plc is one of the world's largest owners and operators of product tankers, specializing in the transportation of refined oil products like gasoline, jet fuel, and diesel. Operating under its integrated 'One TORM' model, the company maintains a modern, wholly-owned fleet of nearly 90 vessels. It is widely recognized by investors for its aggressive variable dividend policy, which returns a significant portion of its cash flow directly to shareholders during periods of high freight rates.
Read more on TRMD →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →